A PLK4 inhibitor has single-agent activity in preclinical tumor models

Area of Science:

• Pharmacology
• Oncology
• Drug Discovery

Background:

• Polo-like kinase 4 (PLK4) is crucial for centriole duplication.
• Dysregulation of PLK4 is implicated in various cancers.
• Targeting PLK4 presents a potential therapeutic avenue for cancer treatment.

Purpose of the Study:

• To evaluate CFI-400945 as a novel Polo-like kinase 4 (PLK4) inhibitor.
• To assess the pharmacokinetic properties and antitumor efficacy of CFI-400945.

Main Methods:

• In vitro enzymatic assays to determine PLK4 inhibition.
• Cell-based assays to assess antiproliferative effects.
• In vivo studies in tumor models to evaluate antitumor activity and bioavailability.

Main Results:

• CFI-400945 demonstrated potent and selective inhibition of PLK4.
• The compound exhibited oral bioavailability.
• Significant antitumor activity was observed in vivo.

Conclusions:

• CFI-400945 is a promising orally bioavailable PLK4 inhibitor.
• Its demonstrated in vivo antitumor activity supports further clinical development.
• PLK4 inhibition represents a viable strategy for cancer therapy.